* Terumo Blood and Cell Technologies' new Rika system represents a new era in plasma collections
Rika, currently in limited market release, represents a new era in plasma collections. The system, cleared for use by the
CSL Plasma's decision to work with Terumo Blood and Cell Technologies is in line with its business goals to improve its donor and employee experiences through innovation. Entering the source plasma market is a natural extension of Terumo Blood and Cell Technologies' experience and global leadership in apheresis technology.
"We designed the Rika ecosystem, including the software and services, in response to the industry's need for technological advancement and process improvements to drive efficiency and quality while maintaining donor safety and a sufficient plasma supply," says
The proprietary design of the Rika Plasma Donation System's centrifuge maximizes the plasma yield per cycle, which enables an average collection time of 35 minutes or less. Rika ensures there is never more than 200 milliliters of blood outside the donor's body at one time.
CSL Plasma is first implementing Rika at its
ENDS
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in
Media Contacts:
Tel +44 (0)20 89434685
matthew@ibcomms.agency / michelle@ibcomms.agency
.
(C) 2022 M2 COMMUNICATIONS, source